1529807-51-9

Basic information

• Product Name: [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate
• Synonyms: [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate
• CAS NO: 1529807-51-9
• Molecular Weight: 264.081
• Mol File: 1529807-51-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate(1529807-51-9)
• EPA Substance Registry System: [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate(1529807-51-9)

Safety Data

• Hazardous Substances Data: 1529807-51-9(Hazardous Substances Data)

Usage

General Description

[¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate is a radio-labeled compound used in biochemical and pharmacological research. It is a derivative of the amino acid glycine, with a methyl group and a dichlorobenzoyl group attached to the amino group of glycine. The presence of the radio-labeled carbon-14 allows for tracking and tracing the compound in biological systems. This chemical is commonly used in experiments to study the metabolism, absorption, distribution, and excretion of drugs and other compounds in living organisms. Additionally, it can be utilized in the synthesis of pharmaceuticals and in the investigation of enzyme activity and kinetics.

Upstream product

• 1435-50-3 2-bromo-1,4-dichlorobenzene 
• 108055-34-1 [¹⁴C]-2,5-dichlorobenzoic acid 
• 616-34-2 methoxycarbonylmethylamine 

Downstream Products

• 1529807-52-0 [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid 
• 1529807-53-1 [¹⁴C]-2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioaxaborol-2-yl]butyl}amino)-2-oxoethyl]benzamide 
• 1529807-54-2 [¹⁴C]-(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid 
• 1529807-55-3 [¹⁴C]-(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid 

Relevant articles and documents

Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708

MLN9708 (ixazomib citrate) is an investigational, orally bioavailable proteasome inhibitor that is under development by Millennium in clinical studies in both hematologic and nonhematologic malignancies. The stable isotope-labeled MLN9708 was required for bio-analytical studies. [13C 9]-MLN9708 (11) was synthesized in seven steps from the uniformly labeled [13C6]-1,4-dichlorobenzene (3) and [1- 13C]-acetyl chloride. Because of the presence of two chlorine atoms and a boron atom, compound 6 was further reacted with [13C 2]-glycine to provide an internal standard that is well separated from the parent compound during mass spectrometric analysis. The radiolabeled version was prepared to support metabolite profiling and whole body autoradiography studies in experimental animals. [14C]-MLN9708 (19) was synthesized in six steps from commercially available [14C]-barium carbonate. The key intermediate, [carboxyl-14C]-2,5-dichlorobenzoic acid (14), was prepared by selective lithiation of 1-bromo-2,5-dichlorobenzene (12) followed by carbonation with [14C]-barium carbonate. In preparation for a one-time human absorption, distribution, metabolism and excretion (ADME) study, the stability of [14C]-MLN9708 and its precursors were also evaluated. Copyright